Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Operating activities
Net income	$ 312,442	$ 326,661	$ 28,067
Adjustments to reconcile net income to net cash flows from operating activities:
Depreciation, amortization and accretion	64,624	60,043	47,929
Impairment of long-lived assets	0	138,050	0
Asset retirement obligation acceleration	0	0	280
Gain on interest rate swap termination	0	0	(5,494)
Amortization of debt related costs	4,296	4,300	1,249
Changes in fair value of contingent assets and liabilities	(2,699)	(9,275)	34,700
Charges incurred in connection with acquired IPR&D	66,000	0	260,000
Loss on extinguishment of debt	0	0	588
Provision for excess and obsolete inventory	(904)	7,914	7,145
Stock-based compensation	76,393	50,507	29,262
Gain on disposal of assets	(8,415)	(51,789)	0
Unrealized loss on investment in equity securities	43,564	0	0
Deferred taxes	(30,029)	(55,632)	(48,016)
Long-term indemnification receivable	0	3,929	9,554
Long-term income tax payable and other long-term liabilities	5,236	(3,103)	(12,477)
Other	12,194	4,855	4,059
Changes in assets and liabilities which provided (used) cash:
Accounts receivable	(37,685)	(68,637)	(128,460)
Inventory	(2,670)	(36,220)	(7,508)
Other current assets	4,440	(2,418)	(2,440)
Other long-term assets	0	0	(533)
Accounts payable	(8,804)	17,189	301
Accrued expenses and other liabilities	46,767	(81,114)	63,575
Net cash provided by operating activities	544,750	305,260	281,781
Investing activities
Capital expenditures	(51,625)	(46,555)	(18,347)
Proceeds from sale of assets, net	17,767	97,839	1,800
Purchases of investment in equity securities	(83,246)	0	0
Acquisition of assets, net	(80,911)	(45,345)	(260,000)
Acquisition of exclusive license option	(28,000)	0	0
Net cash (used in) provided by investing activities	(226,015)	5,939	(276,547)
Financing activities
Proceeds from issuance of common stock	3,450	1,933	1,375
Debt issuance costs	0	0	(95)
Proceeds from issuance of long-term debt, net	0	0	557,750
Contingent value rights settlement	0	(3,700)	0
Payments on long-term debt and other borrowings	(318)	(717)	(175,385)
Deferred financing costs	(2,331)	0	(2,315)
Proceeds from interest rate swap termination	0	0	5,583
Proceeds from stock option exercises	3,278	3,816	7,537
Payments for minimum statutory tax withholding related to net share settlement of equity awards	(22,615)	(14,394)	(7,759)
Repurchase of common stock	(100,000)	0	(75,000)
Net cash (used in) provided by financing activities	(118,536)	(13,062)	311,691
Effect of foreign exchange rates on cash and cash equivalents	(998)	(93)	(335)
Net increase in cash and cash equivalents and restricted cash	199,201	298,044	316,590
Cash and cash equivalents and restricted cash, beginning of year	715,285	417,241	100,651
Cash and cash equivalents and restricted cash, end of year	914,486	715,285	417,241
Reconciliation to amounts within the consolidated balance sheets
Cash and cash equivalents	912,814	713,656	415,652
Restricted cash included in other long-term assets	1,672	1,629	1,589
Cash, cash equivalents and restricted cash at end of period	914,486	715,285	417,241
Supplemental disclosure of cash flow information
Interest	15,094	15,387	5,064
Income taxes, net of refunds of $2,688, $25 and $50, respectively	153,815	151,579	54,049
Schedule of non-cash investing and financing activities
Additions of property, plant and equipment included in liabilities	5,058	6,978	2,370
Lease liability settled through transfer of lease	762	0	0
Right-of-use asset obtained in exchange for operating lease liabilities	63	29,396	11,019
Excise tax payable on net common stock repurchases	$ 251	$ 0	$ 0